MAK16 Antibody

Fundamental Characteristics

What is the MAK16 protein that anti-MAK16 antibodies target?

MAK16 (protein MAK16 homolog) is a nuclear protein with a canonical length of 300 amino acid residues and a molecular mass of 35.4 kDa in humans. It belongs to the MAK16 protein family and has several synonyms including NNP78, RNA binding motif protein 13, and RNA binding protein. The protein is primarily localized in the nucleus, suggesting its involvement in nuclear processes .

In which species has the MAK16 protein been identified?

MAK16 gene orthologs have been documented across multiple vertebrate species. Research has confirmed the presence of MAK16 orthologs in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken models. This conservation across species indicates the protein's evolutionary importance and provides multiple model systems for comparative studies .

What are the most common applications for anti-MAK16 antibodies in research?

The predominant application for anti-MAK16 antibodies is Western Blot (WB), which is used to detect and quantify the MAK16 protein in cell or tissue lysates. Other common applications include Enzyme-Linked Immunosorbent Assay (ELISA), Immunocytochemistry (ICC), and Immunofluorescence (IF). These techniques allow for detection, localization, and quantification of MAK16 in various experimental contexts .

Methodological Considerations

What types of anti-MAK16 antibodies are available for research?

Multiple types of anti-MAK16 antibodies are available, including polyclonal antibodies (pAb) derived from rabbit and monoclonal antibodies. These antibodies come in various forms including unconjugated versions and those available with biotin conjugation. The selection depends on the specific research application and detection system employed .

How should I validate an anti-MAK16 antibody before using it in my research?

Validation should include multiple steps: (1) Western blot analysis to confirm the antibody detects a protein of the expected molecular weight (approximately 35.4 kDa for MAK16); (2) Testing on positive and negative control samples; (3) If possible, using siRNA knockdown of MAK16 to confirm specificity; (4) Cross-referencing results with a second antibody targeting a different epitope of MAK16. For critical applications, additional validation through immunoprecipitation followed by mass spectrometry can provide definitive confirmation of specificity .

What sample preparation techniques are recommended for detecting MAK16 in Western blots?

For optimal detection of MAK16 in Western blots, cells or tissues should be lysed in a buffer containing protease inhibitors to prevent degradation. Nuclear extraction protocols may improve detection since MAK16 is primarily located in the nucleus. Standard SDS-PAGE sample preparation with heat denaturation at 95°C for 5 minutes is typically sufficient. For membrane transfer, PVDF membranes are often preferred for nuclear proteins like MAK16, with a blocking step using 5% non-fat milk or BSA in TBST .

Experimental Design

How can I design experiments to investigate MAK16's potential role in RNA processing?

Given MAK16's classification as an RNA binding protein, investigations into its RNA processing functions require a multi-faceted approach: (1) RNA immunoprecipitation (RIP) assays using anti-MAK16 antibodies to identify bound RNA species; (2) Cross-linking immunoprecipitation (CLIP-seq) to map binding sites with nucleotide resolution; (3) RNA-seq following MAK16 knockdown or knockout to identify transcripts affected by its absence; (4) Co-immunoprecipitation with anti-MAK16 antibodies followed by mass spectrometry to identify protein interaction partners in RNA processing complexes; (5) Structural studies combining X-ray crystallography or cryo-EM with immunological techniques to visualize MAK16-RNA interactions .

What considerations should be made when using anti-MAK16 antibodies for immunoprecipitation studies?

Successful immunoprecipitation with anti-MAK16 antibodies requires careful planning: (1) Select antibodies specifically validated for immunoprecipitation applications, as not all anti-MAK16 antibodies perform equally in this context; (2) Optimize lysis conditions to preserve protein-protein interactions while effectively extracting nuclear proteins; (3) Consider cross-linking with formaldehyde for transient interactions; (4) Include appropriate negative controls using isotype-matched irrelevant antibodies; (5) Verify precipitated material by Western blot or mass spectrometry; (6) For RNA-binding studies, include RNase inhibitors in buffers and consider UV cross-linking to stabilize protein-RNA interactions .

How can I establish a quantitative ELISA for measuring anti-MAK16 autoantibodies in clinical samples?

Developing a quantitative ELISA for anti-MAK16 autoantibodies requires: (1) Coat 96-well plates with purified recombinant MAK16 protein at an optimized concentration; (2) Block with an appropriate buffer (typically BSA or non-fat milk solution); (3) Add serially diluted patient sera or control samples; (4) Detect bound antibodies using horseradish peroxidase-labeled anti-human IgG; (5) Generate a standard curve using known positive samples; (6) Include multiple controls (blank, negative sera, positive sera); (7) Determine the optimal cutoff value by testing numerous healthy and disease samples; (8) Validate the assay with external sample cohorts to confirm sensitivity and specificity .

Clinical Research Applications

How has anti-MAK16 been evaluated as a biomarker for systemic lupus erythematosus (SLE)?

Research has identified anti-MAK16 as a potential novel autoantibody biomarker for SLE diagnosis. In validation studies using both protein microarray and ELISA methods, anti-MAK16 autoantibodies were found at significantly higher levels in SLE patients compared to healthy volunteers and disease controls. When integrated into diagnostic panels with other autoantibodies such as anti-RPLP2, anti-PARP1, and anti-RPL7A, it improved discrimination between SLE and control groups. The area under the curve (AUC) of the receiver operator characteristic (ROC) curve for anti-MAK16 ELISA tests showed values of 0.698 and 0.671 for SLE vs. healthy volunteers and SLE vs. disease controls, respectively, indicating moderate diagnostic potential .

What methodological challenges exist in using anti-MAK16 antibodies for tissue immunohistochemistry?

Several methodological challenges must be addressed when using anti-MAK16 antibodies for tissue immunohistochemistry: (1) Antigen retrieval optimization is critical since nuclear proteins can be masked during fixation; (2) Background signal must be carefully controlled, particularly with polyclonal antibodies; (3) Antibody dilution requires thorough titration to balance specific signal and background; (4) Proper controls, including tissues with known MAK16 expression levels and negative controls using isotype-matched irrelevant antibodies, are essential; (5) Cross-reactivity with other RNA-binding proteins must be evaluated; (6) Nuclear localization pattern should be confirmed with counterstains; (7) Signal amplification systems may be needed for low-abundance expression; (8) Validation across multiple tissue types is recommended to account for tissue-specific variations in fixation and processing requirements .

How can multiplexed detection systems be designed to simultaneously measure anti-MAK16 and other autoantibodies in clinical samples?

Designing multiplexed detection systems requires: (1) Selection of compatible antibody pairs that don't cross-react; (2) Optimization of a shared buffer system that maintains activity of all components; (3) Implementation of distinct reporter systems (different fluorophores, enzyme substrates, or bead populations); (4) Development using platform technologies such as Luminex bead-based assays, protein microarrays, or multiplex ELISA systems; (5) Validation of each analyte independently before combination to establish baseline performance; (6) Evaluation of potential interference between analytes in the multiplexed format; (7) Creation of a standardized analysis pipeline capable of interpreting multi-parameter data; (8) Inclusion of calibrators and controls for each analyte in the multiplex panel .

Technical Optimization

What strategies can improve the detection sensitivity of MAK16 in low-expression tissues?

Enhancing MAK16 detection in tissues with low expression levels requires: (1) Signal amplification using tyramide signal amplification (TSA) or other enzymatic amplification systems; (2) Implementation of more sensitive detection methodologies like proximity ligation assay (PLA); (3) Concentration of samples through subcellular fractionation to enrich nuclear proteins; (4) Use of more sensitive immunoprecipitation techniques prior to detection; (5) Employment of highly sensitive chemiluminescent or fluorescent detection reagents; (6) Application of antigen retrieval protocols specifically optimized for nuclear proteins; (7) Selection of antibodies with higher affinity and specificity for MAK16; (8) Reduction of background through careful blocking optimization and use of specialized blocking reagents for the tissue type being examined .

How can I troubleshoot inconsistent results when using anti-MAK16 antibodies across different experimental platforms?

Inconsistent results can be addressed by: (1) Standardizing sample preparation protocols across platforms; (2) Validating antibody performance in each specific application independently; (3) Testing multiple antibody lots and maintaining consistency once an effective lot is identified; (4) Implementing more rigorous positive and negative controls specific to each platform; (5) Optimizing protein extraction methods to ensure complete solubilization of nuclear proteins; (6) Adjusting blocking agents and antibody concentrations for each platform; (7) Considering the impact of fixation methods on epitope availability; (8) Evaluating the influence of post-translational modifications on antibody recognition across different experimental conditions or cell types .

MAK16 Protein Characteristics

What comparative information is available to guide selection of anti-MAK16 antibodies for specific applications?

This comparative table synthesizes information from available antibody products to guide researchers in selecting and optimizing anti-MAK16 antibodies for specific applications .